Navigation Links
Isolagen Receives Bridge Financing to Allow it to Seek Debtor-in-Possession Financing in Connection With a Possible Filing Under Chapter 11 of the United States Bankruptcy Code
Date:5/6/2009

Isolagen Common Stock to be halted from trading on the NYSE Amex

EXTON, Pa., May 6 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (NYSE Amex: ILE) today announced that the Company has entered into secured promissory notes and security agreements (the "Notes") with eight lenders pursuant to which the Company borrowed an aggregate of $500,417.00 in principal amount. The Notes bear interest at a rate of 20% per annum with principal and interest on the Notes due on the earlier of June 20, 2009 or the date that the Company files for voluntary or involuntary bankruptcy.

If the Company receives debtor-in-possession financing in any bankruptcy proceeding, the holders of the Notes shall have the right to exchange the face amount of the Notes, plus any accrued but unpaid interest, into such debtor-in-possession financing on the same terms and conditions as the debtor-in-possession financing on a pari passu basis and on a dollar-for-dollar basis. To secure the repayment of the Notes, the Company granted the holders of the Notes a security interest in and a lien on the Company's 57% equity interest in Agera Laboratories, Inc.

Viriathus Capital LLC ("Viriathus") acted as the Company's financial advisor and placement agent with respect to the offering of the Notes. Viriathus is also assisting the Company in seeking potential debtor-in-possession financing in connection with the possible filing of a voluntary petition for reorganization relief under Chapter 11 of Title 11 of the United States Bankruptcy Code. If the Company is successful in obtaining commitments for such financing in sufficient amounts, it is likely that the Company will file such a petition. The Company currently has no legal commitments for such financing, and there is no assurance that such financing will be available to the Company on satisfactory terms,
'/>"/>

SOURCE Isolagen, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase II/III Acne Scar Study
2. Isolagen, Inc. Reports Receipt of Initiation of Delisting Proceedings Notice from Amex
3. Isolagen, Inc. Sells Switzerland Facility
4. Isolagen, Inc. Promotes Todd Greenspan to Chief Financial Officer (CFO)
5. Isolagen, Inc. Receives Notification Letter from American Stock Exchange
6. Isolagen Inc. Promotes Declan Daly to Chief Executive Officer (CEO)
7. Isolagen Inc. to Present at the 26th Annual JPMorgan Healthcare Conference
8. Isolagen Modifies Ongoing Clinical Program for Acne Scars
9. Isolagen Initiates Phase III Clinical Program to Investigate Isolagen Therapy(TM) for the Treatment of Acne Scars
10. Isolagen, Inc. Postpones Annual Meeting
11. Bertram Receives Organizational Innovation Award at AONE Conference -- Award Sponsor B. E. Smith Also Announces Funding for Three Seed Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... Inverse Effects of Midlife Occupational and Leisure Time Physical ... occupational physical activity in midlife increases the risk of ... decreases the risk. This is found in a study ... years. The study was conducted at the Gerontology Research ... Health. , Heavy physical labor is often repetitive, wears ...
(Date:4/23/2014)... depletion of self-control, according to research published in ... Psychological Science. , Self-control can be difficult sticking ... a boring textbook are hard things to do. Considerable ... self-control for a long period seems to "deplete" our ... "It is as if self-control is a limited resource ...
(Date:4/23/2014)... of Alzheimer,s disease has been a rapidly evolving ... the latest crook in the research road, scientists ... between proteins associated with the disease. The report, ... Neuroscience , could have important implications for developing ... and colleagues explain that for years, research has ...
(Date:4/22/2014)... industry leaders visited the New Jersey Institute of ... S. Bloom for the launch of the New ... provides a new model for business innovation through ... assets and investment. U.S. Senator Cory Booker, Panasonic ... Taylor, New Jersey Lieutenant Governor Kim Guadagno, New ...
(Date:4/22/2014)... researchers have characterized a set of clock genes that ... types of species, from flies to humans. Over 15 ... there are more. A team from the Perelman School ... big-data approaches could find them. , To accelerate ... professor of Pharmacology and first author Ron Anafi, MD, ...
Breaking Medicine News(10 mins):Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:ADHD drug may help preserve our self-control resources 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Bioinformatics profiling identifies a new mammalian clock gene 2
... networks in fruit flies has led researchers to a sensitive ... most common type of kidney cancer. In the journal ... at the University of Chicago shows that the biomarker known ... renal cell carcinomas but not by normal kidney tissue. , ...
... new 30" in groundbreaking new calendarHAGATNA, Guam, Jan. 27 ... natural calendar to promote her "Look Good Naked" theme ... is beautifully captured au natural and semi-nude in high-quality ... in her beautiful cottage home. "I wanted to show ...
... HCA Healthcare announces the following Webcast:, What: ... 10:00 EST, Where: http://www.videonewswire.com/event.asp?id=55052 , How: ... web at the, ... +1-615 344 ...
... Jan. 27 /PRNewswire-FirstCall/ - QLT Inc. ("QLT") (NASDAQ: ... modified "Dutch Auction" tender offer (the "Offer"), which expired at ... on the preliminary report of the depository for the Offer, ... shares (the "Shares") at a price of US$2.50 per Share, ...
... -- The University of Texas at San Antonio (UTSA) ... College of Engineering has been awarded a $199,884, 24-month ... energy combustion. , "This is one of the first ... combustion, gasification and energy efficiency," said Efstathios Michaelides, mechanical ...
... adds affordable, professionally refurbished Hill-Rom hospital beds to its ... ... -- DRE Medical Equipment — named by Business First of Louisville ... refurbished Hill-Rom hospital beds . DRE’s extensive lineup of economically-priced ...
Cached Medicine News:Health News:Roadkill study could speed detection of kidney cancer 2Health News:QLT announces preliminary results of tender offer 2Health News:QLT announces preliminary results of tender offer 3Health News:UTSA receives federal funding for fossil fuel research 2Health News:DRE Medical Equipment Now Sells Reconditioned Hill-Rom Hospital Beds 2Health News:DRE Medical Equipment Now Sells Reconditioned Hill-Rom Hospital Beds 3
(Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: